Cited by 457Metabolism, Diabetes, and CancerPeroxisome Proliferator-Activated ReceptorsAdipose Tissue and Metabolism

AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome

Ruderman, Neil, Prentki, Marc·2004·Nature Reviews Drug Discovery

Integrity signals

Registry

Crossref · 10.1038/nrd1344

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Malonyl CoA represses CPT1 to inhibit acylcarnitine import, and its levels dictate the balance of fat synthesis or oxidation within a cell.

    “Malonyl CoA, generated by the enzyme acetyl CoA carboxylase (ACC), represses CPT1 to inhibit acylcarnitine import.53 Malonyl CoA is the initiating metabolite for FAS, and its levels dictate the balance of fat synthesis or oxidation within a cell.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ruderman, N., & Prentki, M.
Affiliations
  • Boston University (US)
  • Centre Hospitalier de l’Université de Montréal (CA)
Venue
Nature Reviews Drug Discovery
Published
2004-04-01
Volume
3
Issue
4
Pages
340-351
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W1983336199
Cited by
451
References
168
Citations by year
2026: 4 · 2025: 13 · 2024: 12 · 2023: 11 · 2022: 23 · 2021: 17 · 2020: 19 · 2019: 21 · 2018: 13 · 2017: 22 · 2016: 19 · 2015: 14 · 2014: 27 · 2013: 22 · 2012: 21
FWCI
2.30
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
AMPK, malonyl-CoA, metabolic syndrome, insulin resistance, obesity, fatty acid metabolism, ectopic fat deposition, AMPK activators, therapeutic target, type 2 diabetes, atherosclerosis
MeSH terms
Adenylate Kinase, Animals, Fatty Acids, Humans, Malonyl Coenzyme A, Signal Transduction, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review